Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: Insights from BOLERO-2

• Main Authors: H. S. Rugo, K. I. Pritchard, M. Gnant, S. Noguchi, M. Piccart, G. Hortobagyi, J. Baselga, A. Perez, M. Geberth, T. Csoszi, E. Chouinard, V. Srimuninnimit, P. Puttawibul, J. Eakle, W. Feng, H. Bauly, M. El-hashimy, T. Taran, H. A. Burris
• 其他作者: UCSF Helen Diller Family Comprehensive Cancer Center
• 格式: Article
• 出版: 2018
• 主題: Medicine
• 在線閱讀: https://repository.li.mahidol.ac.th/handle/123456789/34869
• 機構: Mahidol University

Background: In the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated significant clinical benefit with an acceptable safety profile when administered with exemestane (EXE) in postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer....